Takeda Wants Japan, U.S. To Work Out Prevacid Taxing
This article was originally published in PharmAsia News
Takeda Pharmaceutical is urging the Japanese and U.S. governments to determine which country alone will tax sales of its Prevacid (lansoprazole) ulcer drug. The drug maker already is involved in a 2006 dispute with competing taxing authorities in the two countries over the drug, which Takeda marketed at the time with TAP Pharmaceuticals of the United States. A Takeda subsidiary later absorbed TAP. Takeda's request involves all cross-border product transactions Takeda makes in the two countries. (Click here for more - a subscription may be required
You may also be interested in...
Japanese Tax Authorities Eye New Pharma Targets; Takeda Seeks To Resolve Double Taxation On Prevacid
TOKYO - Japanese tax authorities increasingly are looking at management costs during transfer-pricing investigations of pharmaceutical companies, shifting away from a focus on overseas R&D costs
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.